Fig. 3.
Fig. 3. Bindability of human IgE to the FcɛRI on human platelets analyzed by flow cytometry. The platelets were (A) untreated (dashed line; only FITC-labeled goat antihuman IgE, solid dark line; human myeloma IgE plus FITC-labeled goat antihuman IgE), (B) pretreated with isotype-matched control Ab (dotted line; only FITC-labeled goat antihuman IgE, dashed line; human myeloma IgE plus FITC-labeled goat antihuman IgE, solid dark line; pretreated with mouse IgG1), (C) pretreated with mouse MoAb to human FcɛRI  chain (CRA2) (dotted line; only FITC-labeled goat antihuman IgE, dashed line; human myeloma IgE plus FITC-labeled goat antihuman IgE, solid dark line; pretreated with CRA2). These results shown are representative of 10 independent experiments.

Bindability of human IgE to the FcɛRI on human platelets analyzed by flow cytometry. The platelets were (A) untreated (dashed line; only FITC-labeled goat antihuman IgE, solid dark line; human myeloma IgE plus FITC-labeled goat antihuman IgE), (B) pretreated with isotype-matched control Ab (dotted line; only FITC-labeled goat antihuman IgE, dashed line; human myeloma IgE plus FITC-labeled goat antihuman IgE, solid dark line; pretreated with mouse IgG1), (C) pretreated with mouse MoAb to human FcɛRI  chain (CRA2) (dotted line; only FITC-labeled goat antihuman IgE, dashed line; human myeloma IgE plus FITC-labeled goat antihuman IgE, solid dark line; pretreated with CRA2). These results shown are representative of 10 independent experiments.

Close Modal

or Create an Account

Close Modal
Close Modal